As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.

Mass Gen's Dr. Ali Raja explains why some were sent to the emergency room after using semaglutide injections. Raja says some of the symptoms people experienced won't require an ER visit. Raja says not ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

Novo Nordisk and a popular virtual health company are making Wegovy more accessible to millions of more Americans.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Hims & Hers Health (NYSE: HIMS), once a niche telehealth provider focused on men’s wellness, has rapidly transformed into a formidable player in the broader digital health ecosystem. HIMS stock has ...

Patients either got a weekly 2.4 milligram dose of semaglutide, the active ingredient ... compared with 34.3% of people who got a placebo. Prior to starting the trial, the participants also ...

The filmmaker’s candid post opens a conversation about health, stigma, and promising advances in diabetes and weight ...

Even though the study used the starting dose of semaglutide in diabetes formulation Ozempic – the lowest on the market – the results suggest the drug could be more effective than drugs ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...